Tue, Oct 21, 2014, 10:38 AM EDT - U.S. Markets close in 5 hrs 22 mins

Recent

% | $
Quotes you view appear here for quick access.

VMware, Inc. Message Board

maybeesornot 8 posts  |  Last Activity: Oct 19, 2014 11:01 AM Member since: Aug 5, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    the reason for the drop

    by maybeesornot Oct 18, 2014 2:25 AM
    maybeesornot maybeesornot Oct 19, 2014 11:01 AM Flag

    As stated above its not possible to know exactly how they make revenue on vasoscan .
    But I believe that mhcc provide full services as to the test and the billing .
    they get a fee per test , and if they also do the billing for the test its easy to track and monitor.
    But I still think to make the projected dramatically increase in rev they have to provide full service.
    So I am looking for a good increase in revenue for their billing and coding to be a indication of the full service.
    As stated by the company about the contracts and the potential revenue ,I think all billing has to go true mhcc billing service to be able to capture al the revenue.
    CDx Diagnostics t bill $85 for analyzing the brush test to their insurer .
    I am hoping this billing also will go true mhcc billing division and it’s a part of the deal.

    Sentiment: Strong Buy

  • Reply to

    the reason for the drop

    by maybeesornot Oct 18, 2014 2:25 AM
    maybeesornot maybeesornot Oct 19, 2014 9:53 AM Flag

    Portions of the distribution agreement with Atossa Genetics Inc., the distribution agreement with CDx Diagnostics Inc., the distribution agreement with Heart Smart Inc., the distribution agreement with eWellness Corporation have been omitted and filed separately with the SEC pursuant to a request for confidential treatment.

    Sentiment: Strong Buy

  • maybeesornot maybeesornot Oct 19, 2014 7:36 AM Flag

    Delta Dental benefit plans that currently offer coverage for oral surgery will automatically cover brush biopsy at the same level as other oral surgeries are covered. Other plans may elect to cover brush biopsy by contacting their Account Manager. We have decided to offer coverage for this procedure because of its proven ability to detect precancerous and cancerous cells.

  • OralCDx is also listed but if you click on it it’s not working yet

    Sentiment: Strong Buy

  • Costs of OralCDx and Billing for
    the Procedure
    The dentist charges for performing the brush biopsy,
    and in many cases, dental insurance companies will
    cover the fee. Complete billing instructions and
    codes available to report the dentist’s procedure to
    the patient’s insurance company are supplied in each
    kit. Keep in mind that other early cancer detection
    tests such as the mammogram and PSA for prostate
    cancer are often billed as fee for service procedures.
    Some of your patients may be accustomed to this
    practice.
    As an alternative to billing dental insurance or
    collecting fee for service, Medicare and almost all
    medical insurance companies reimburse the dentist
    for performing an oral biopsy (brush and scalpel).
    Several independent companies provide a service
    whereby medical insurance claims (including
    Medicare) for the brush biopsy procedure are filed
    on behalf of dentists. For a list of these companies,
    call 1-877-672-5722.
    CDx Laboratories charge the patient’s insurance $85
    for analyzing the brush biopsy specimen. Simply
    provide all of the insurance information in the
    requested space on the form that accompanies your
    patient’s biopsy specimen. The patient is billed for
    the portion that is not covered by their insurance.

  • Reply to

    the reason for the drop

    by maybeesornot Oct 18, 2014 2:25 AM
    maybeesornot maybeesornot Oct 18, 2014 11:15 AM Flag

    And katherine if I may ask .
    Do you think the billing is also in the contract`s .
    So that they can provide the tests ,and gif full services as to the billing

    Sentiment: Strong Buy

  • Reply to

    the reason for the drop

    by maybeesornot Oct 18, 2014 2:25 AM
    maybeesornot maybeesornot Oct 18, 2014 10:51 AM Flag

    Katherine I am fully aware that the breast aspirator isn’t in the equation for Q3 revenues.
    As I stated I don’t even think it was for Q4 .
    But as to old news ,I havened came across any post that this was mentioned.
    And I am wondering if other MB posters know about it.
    In my believe this could be the reason of us going down .

  • maybeesornot by maybeesornot Oct 18, 2014 2:25 AM Flag

    On 23 of September the FDA did not clear the ForeCYTE breast Aspirator .this means mhcc basically lost their 4e test to bring to marked .go to the Atossa genetics site for the PR .now the ForeCYTE kit was not FDA cleared I do not think it was included in the contracts they already have in place .and so I do not think it was included in the statement's made about the potential revenue for Q4 .although its a setback its possible mhcc will now try to participate in the lunch of the FullCYTE Breast Aspirator because its FDA cleared and its now the commercial focus of Attosa . I have sold out AVNR and IG in the last week after a great return on my investment and have a position now in mhcc of 112,000 long at 0,287 and 25,000 to trade the swings .my long position will be at leased until Q3 2015 numbers are out to see a year of commercialisation of the medical device division of mhcc .and for Q3 numbers I will be impressed if they make revenue of $500,000 or more ,I am thinking between $200,000 and $400,000 because the limited funds mhcc haves (2 mil in cash and receivables at June 30,2014) good luck to all longs

    Sentiment: Strong Buy

VMW
88.19+0.53(+0.60%)10:38 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.